The University of Southampton
University of Southampton Institutional Repository

Uncovering the burden of hidden ciliopathies in the 100 000 Genomes Project: a reverse phenotyping approach

Uncovering the burden of hidden ciliopathies in the 100 000 Genomes Project: a reverse phenotyping approach
Uncovering the burden of hidden ciliopathies in the 100 000 Genomes Project: a reverse phenotyping approach

Background The 100 000 Genomes Project (100K) recruited National Health Service patients with eligible rare diseases and cancer between 2016 and 2018. PanelApp virtual gene panels were applied to whole genome sequencing data according to Human Phenotyping Ontology (HPO) terms entered by recruiting clinicians to guide focused analysis. Methods We developed a reverse phenotyping strategy to identify 100K participants with pathogenic variants in nine prioritised disease genes (BBS1, BBS10, ALMS1, OFD1, DYNC2H1, WDR34, NPHP1, TMEM67, CEP290), representative of the full phenotypic spectrum of multisystemic primary ciliopathies. We mapped genotype data 'backwards' onto available clinical data to assess potential matches against phenotypes. Participants with novel molecular diagnoses and key clinical features compatible with the identified disease gene were reported to recruiting clinicians. Results We identified 62 reportable molecular diagnoses with variants in these nine ciliopathy genes. Forty-four have been reported by 100K, 5 were previously unreported and 13 are new diagnoses. We identified 11 participants with unreportable, novel molecular diagnoses, who lacked key clinical features to justify reporting to recruiting clinicians. Two participants had likely pathogenic structural variants and one a deep intronic predicted splice variant. These variants would not be prioritised for review by standard 100K diagnostic pipelines. Conclusion Reverse phenotyping improves the rate of successful molecular diagnosis for unsolved 100K participants with primary ciliopathies. Previous analyses likely missed these diagnoses because incomplete HPO term entry led to incorrect gene panel choice, meaning that pathogenic variants were not prioritised. Better phenotyping data are therefore essential for accurate variant interpretation and improved patient benefit.

genetics, medical, genomics
0022-2593
1151-1164
Best, Sunayna
69abeca2-f2cb-41fb-a3c4-8a46b4962710
Yu, Jing
5fd9d3a3-5552-4a34-be88-a6a14f95eaf4
Lord, Jenny
e1909780-36cd-4705-b21e-4580038d4ec6
Roche, Matthew
ae67c475-b6a7-4bbd-8cd4-d7f046ff6f20
Watson, Christopher M.
83b46b74-e6a1-4ee9-8078-c69693de008a
Bevers, Roel P J
3ebbe106-524a-4cfd-99ff-32dd27dc1a86
Stuckey, Alex
1d13040c-8966-4c3c-afca-cfe62e2b9207
Madhusudhan, Savita
d4ba51be-8292-4ce6-9953-503c1a6e5e3c
Jewell, Rosalyn
a1e0e019-b0b1-4eb0-9563-3553865cd8b0
Sisodiya, Sanjay M.
442600da-eda0-410b-97bb-cde8326d702d
Lin, Siying
a5f9720b-f9ef-46e5-90fc-c91d20438d3c
Turner, Stephen
a51d875a-66bb-4a18-b5b0-18ce3dc7d15c
Robinson, Hannah
7c6b21e1-53e9-4e50-8cc1-b0cf507ddf91
Joseph, Leslie
aaa98fab-d98a-4ef2-9f0b-c058b0492237
Baple, Emma
3c26ed20-f1d8-465c-9c20-badd025bb731
Toomes, Carmel
7c1e8471-3578-459c-b08a-3836e5485b5c
Inglehearn, Chris F.
83e4579c-b071-40c5-b220-5ca9d591e86b
Wheway, Gabrielle
2e547e5d-b921-4243-a071-2208fd4cc090
Johnson, Colin A.
a34c9932-8edc-406f-b45f-16b984a379c0
Genomics England Research Consortium
Best, Sunayna
69abeca2-f2cb-41fb-a3c4-8a46b4962710
Yu, Jing
5fd9d3a3-5552-4a34-be88-a6a14f95eaf4
Lord, Jenny
e1909780-36cd-4705-b21e-4580038d4ec6
Roche, Matthew
ae67c475-b6a7-4bbd-8cd4-d7f046ff6f20
Watson, Christopher M.
83b46b74-e6a1-4ee9-8078-c69693de008a
Bevers, Roel P J
3ebbe106-524a-4cfd-99ff-32dd27dc1a86
Stuckey, Alex
1d13040c-8966-4c3c-afca-cfe62e2b9207
Madhusudhan, Savita
d4ba51be-8292-4ce6-9953-503c1a6e5e3c
Jewell, Rosalyn
a1e0e019-b0b1-4eb0-9563-3553865cd8b0
Sisodiya, Sanjay M.
442600da-eda0-410b-97bb-cde8326d702d
Lin, Siying
a5f9720b-f9ef-46e5-90fc-c91d20438d3c
Turner, Stephen
a51d875a-66bb-4a18-b5b0-18ce3dc7d15c
Robinson, Hannah
7c6b21e1-53e9-4e50-8cc1-b0cf507ddf91
Joseph, Leslie
aaa98fab-d98a-4ef2-9f0b-c058b0492237
Baple, Emma
3c26ed20-f1d8-465c-9c20-badd025bb731
Toomes, Carmel
7c1e8471-3578-459c-b08a-3836e5485b5c
Inglehearn, Chris F.
83e4579c-b071-40c5-b220-5ca9d591e86b
Wheway, Gabrielle
2e547e5d-b921-4243-a071-2208fd4cc090
Johnson, Colin A.
a34c9932-8edc-406f-b45f-16b984a379c0

Best, Sunayna, Yu, Jing and Lord, Jenny , Genomics England Research Consortium (2022) Uncovering the burden of hidden ciliopathies in the 100 000 Genomes Project: a reverse phenotyping approach. Journal of Medical Genetics, 59 (12), 1151-1164, [108476]. (doi:10.1136/jmedgenet-2022-108476).

Record type: Article

Abstract

Background The 100 000 Genomes Project (100K) recruited National Health Service patients with eligible rare diseases and cancer between 2016 and 2018. PanelApp virtual gene panels were applied to whole genome sequencing data according to Human Phenotyping Ontology (HPO) terms entered by recruiting clinicians to guide focused analysis. Methods We developed a reverse phenotyping strategy to identify 100K participants with pathogenic variants in nine prioritised disease genes (BBS1, BBS10, ALMS1, OFD1, DYNC2H1, WDR34, NPHP1, TMEM67, CEP290), representative of the full phenotypic spectrum of multisystemic primary ciliopathies. We mapped genotype data 'backwards' onto available clinical data to assess potential matches against phenotypes. Participants with novel molecular diagnoses and key clinical features compatible with the identified disease gene were reported to recruiting clinicians. Results We identified 62 reportable molecular diagnoses with variants in these nine ciliopathy genes. Forty-four have been reported by 100K, 5 were previously unreported and 13 are new diagnoses. We identified 11 participants with unreportable, novel molecular diagnoses, who lacked key clinical features to justify reporting to recruiting clinicians. Two participants had likely pathogenic structural variants and one a deep intronic predicted splice variant. These variants would not be prioritised for review by standard 100K diagnostic pipelines. Conclusion Reverse phenotyping improves the rate of successful molecular diagnosis for unsolved 100K participants with primary ciliopathies. Previous analyses likely missed these diagnoses because incomplete HPO term entry led to incorrect gene panel choice, meaning that pathogenic variants were not prioritised. Better phenotyping data are therefore essential for accurate variant interpretation and improved patient benefit.

Text
Best et al 2022 - Accepted Manuscript
Download (13MB)
Text
jmedgenet-2022-108476.full - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 7 June 2022
Published date: December 2022
Additional Information: Funding Information: Funding SB acknowledges support from the Wellcome Trust 4Ward North Clinical PhD Academy (ref. 203914/Z/16/Z). JY acknowledges support from Retina UK (grant HMR03950). GW acknowledges support from Wellcome Trust Seed Award (ref. 204378/Z/16/Z). CAJ acknowledges support from Medical Research Council project grants MR/M000532/1 and MR/T017503/1. JL is supported by a National Institute for Health Research (NIHR) Research Professorship awarded to Professor Diana Baralle (DB NIHR RP-2016- 07- 011). SMS is supported by the Epilepsy Society and the NIHR University College London Hospitals Biomedical Research Centre. This research was made possible through access to the data and findings generated by the 100 000 Genomes Project. The 100 000 Genomes Project is managed by Genomics England Ltd (a wholly owned company of the Department of Health and Social Care). The 100 000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100 000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. Funding Information: SB acknowledges support from the Wellcome Trust 4Ward North Clinical PhD Academy (ref. 203914/Z/16/Z). JY acknowledges support from Retina UK (grant HMR03950). GW acknowledges support from Wellcome Trust Seed Award (ref. 204378/Z/16/Z). CAJ acknowledges support from Medical Research Council project grants MR/M000532/1 and MR/T017503/1. JL is supported by a National Institute for Health Research (NIHR) Research Professorship awarded to Professor Diana Baralle (DB NIHR RP-2016-07-011). SMS is supported by the Epilepsy Society and the NIHR University College London Hospitals Biomedical Research Centre.This research was made possible through access to the data and findings generated by the 100 000 Genomes Project. The 100 000 Genomes Project is managed by Genomics England Ltd (a wholly owned company of the Department of Health and Social Care). The 100 000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100 000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. Publisher Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Keywords: genetics, medical, genomics

Identifiers

Local EPrints ID: 468233
URI: http://eprints.soton.ac.uk/id/eprint/468233
ISSN: 0022-2593
PURE UUID: ac70b0b0-6943-4ea2-aeae-f5edaf627ca9
ORCID for Jenny Lord: ORCID iD orcid.org/0000-0002-0539-9343
ORCID for Gabrielle Wheway: ORCID iD orcid.org/0000-0002-0494-0783

Catalogue record

Date deposited: 08 Aug 2022 16:38
Last modified: 17 Mar 2024 07:24

Export record

Altmetrics

Contributors

Author: Sunayna Best
Author: Jing Yu
Author: Jenny Lord ORCID iD
Author: Matthew Roche
Author: Christopher M. Watson
Author: Roel P J Bevers
Author: Alex Stuckey
Author: Savita Madhusudhan
Author: Rosalyn Jewell
Author: Sanjay M. Sisodiya
Author: Siying Lin
Author: Stephen Turner
Author: Hannah Robinson
Author: Leslie Joseph
Author: Emma Baple
Author: Carmel Toomes
Author: Chris F. Inglehearn
Author: Colin A. Johnson
Corporate Author: Genomics England Research Consortium

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×